je.st
news
Tag: amgen
U.S. judge rejects Amgen bid to block 'biosimilar' Neupogen
2015-03-19 22:40:00| Biotech - Topix.net
A U.S. judge on Thursday denied Amgen Inc's bid to block the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, Amgen's blockbuster drug used to prevent infections in cancer patients. The drug, Zarxio, contains the same active ingredient as Amgen's $1.2 billion-a-year Neupogen, and once launched, would become the first biosimilar in the United States.
Amgen Has Been Flat For The Past 4 Months
2015-03-14 08:57:08| Biotech - Topix.net
The dividend was recently increased but the payout ratio is approaching a territory which is a bit high for me. I've been touting the stock for the past couple of years, but now it seems like everyone is jumping on board and makes me think it's near a top.
Amgen to lay off 300 at Onyx, close South S.F. facility
2015-03-11 02:59:33| Biotech - Topix.net
Amgen Inc. will shed roughly 300 of 750 Onyx Pharmaceuticals employees and shutter the South San Francisco facility the giant biotech picked up in its $10 billion acquisition of Onyx less than 18 months ago. The move, following positive news last week on the signature drug of the Amgen-Onyx deal, is the proverbial shoe-drop that Bay Area biotech followers long expected as Thousand Oaks-based Amgen undertakes another restructuring, this time of its cancer drug business.
Investors short Juno Therapeutics, Amgen stocks, but that may not be bad news
2015-03-03 04:12:21| Biotech - Topix.net
More investors were shorting their biotech stocks in the first half of February than in the previous month, according to financial news site Benzinga . Of the top three companies with the most short sells, two have Puget Sound ties: Seattle-based Juno Therapeutics and California-based Amgen , which has offices in Bothell and Seattle until the end of the year.
Amgen says Kyprolis doubles progression-free survival vs Velcade
2015-03-02 04:09:37| Biotech - Topix.net
Amgen Inc's Kyprolis helped patients with relapsed multiple myeloma live twice as long before their blood cancer worsened compared to a regimen containing rival drug Velcade, according to an interim analysis announced by the company on Sunday. REUTERS: Amgen Inc's Kyprolis helped patients with relapsed multiple myeloma live twice as long before their blood cancer worsened compared to a regimen containing rival drug Velcade, according to an interim analysis announced by the company on Sunday.
Tags: survival
doubles
amgen
progressionfree survival
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] next »